Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2021 - 2025)

Historic EPS (Weighted Average and Diluted) for Gyre Therapeutics (GYRE) over the last 10 years, with Q3 2025 value amounting to $0.03.

  • Gyre Therapeutics' EPS (Weighted Average and Diluted) rose 20000.0% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.03, marking a year-over-year increase of 10205.48%. This contributed to the annual value of $0.05 for FY2024, which is 10354.61% up from last year.
  • Latest data reveals that Gyre Therapeutics reported EPS (Weighted Average and Diluted) of $0.03 as of Q3 2025, which was up 20000.0% from $0.01 recorded in Q3 2024.
  • Over the past 5 years, Gyre Therapeutics' EPS (Weighted Average and Diluted) peaked at $1.64 during Q2 2022, and registered a low of -$1.51 during Q4 2023.
  • In the last 5 years, Gyre Therapeutics' EPS (Weighted Average and Diluted) had a median value of $0.01 in 2024 and averaged -$0.22.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 35625.0% in 2022, then crashed by 9878.05% in 2023.
  • Gyre Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.64 in 2021, then tumbled by 48.15% to -$0.95 in 2022, then plummeted by 59.26% to -$1.51 in 2023, then skyrocketed by 100.66% to $0.01 in 2024, then surged by 200.0% to $0.03 in 2025.
  • Its last three reported values are $0.03 in Q3 2025, $0.01 for Q3 2024, and $0.01 during Q2 2024.